Clinical Trial Results

Showing: All studies [change]
Condition: Breast Cancer Location: New Haven, Connecticut 25 trials found
New Search
Filter
Trial Phase
Study Type
FOG-001 in Locally Advanced or Metastatic Solid Tumors
PHASE1, PHASE2INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
PHASE1, PHASE2INTERVENTIONAL Los Angeles, California +4 more
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
NAINTERVENTIONAL New Haven, Connecticut +4 more
RECRUITING
Study of AVZO-021 in Patients With Advanced Solid Tumors
PHASE1, PHASE2INTERVENTIONAL New Haven, Connecticut +4 more
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
PHASE1, PHASE2INTERVENTIONAL Los Angeles, California +4 more
RECRUITING
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
PHASE1INTERVENTIONAL New Haven, Connecticut +4 more
RECRUITING
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
N/AOBSERVATIONAL Duarte, California +4 more
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
PHASE1, PHASE2INTERVENTIONAL New Haven, Connecticut +4 more
RECRUITING
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
PHASE2INTERVENTIONAL Orange, California +4 more
RECRUITING
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NAINTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Pan Tumor Rollover Study
PHASE2INTERVENTIONAL Huntsville, Alabama +4 more
RECRUITING
Exercise in Metastatic Breast Cancer: EMBody
NAINTERVENTIONAL New Haven, Connecticut +4 more
RECRUITING
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
PHASE1, PHASE2INTERVENTIONAL Scottsdale, Arizona +4 more
RECRUITING
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
PHASE1INTERVENTIONAL Tucson, Arizona +4 more
RECRUITING
ATEMPT 2.0: Adjuvant T-DM1 vs TH
PHASE2INTERVENTIONAL San Francisco, California +4 more
RECRUITING
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
PHASE1, PHASE2INTERVENTIONAL Los Angeles, California +4 more
RECRUITING
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PHASE1, PHASE2INTERVENTIONAL Irvine, California +4 more
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
PHASE3INTERVENTIONAL Mobile, Alabama +4 more
RECRUITING
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
PHASE2INTERVENTIONAL Scottsdale, Arizona +4 more
RECRUITING
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
N/AOBSERVATIONAL New Haven, Connecticut +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type